Combining Our Strengths
Leveraging our combined strengths in cutting-edge R&D and rare disease expertise, we strive to advance scientific understanding of rare cancers in order to urgently bring new solutions to this community.
Therapy Areas
Rare Cancers
Striving to advance scientific understanding of rare cancers to bring new solutions.
Innovating in Rare Cancers
Research and development (R&D) for rare cancers share many of the same challenges with other rare diseases—including low prevalence, diagnostic complexity and a lack of treatment options. 1-2
Leveraging AstraZeneca’s oncology expertise and established global footprint, we are exploring new molecular targets and accelerating our pipeline to address unmet medical needs for people living with rare cancers.
Bone Metabolism
Researching and developing innovative treatments that aim to target the underlying causes of rare bone disorders.
Cardiology
Following the science to develop and evaluate potential innovative treatment options to help people living with rare cardiology conditions.
Endocrinology
Identifying potential new opportunities to advance care for those impacted by rare endocrine diseases.
Haematology
Working to improve potential outcomes for more people living with rare haematological diseases worldwide.
Nephrology
Enhancing the understanding of rare renal diseases and accelerating the development of potential therapies.
Neurology
Striving to advance scientific understanding in rare neurology and to accelerate the development of potential life-changing treatments.
References
- Pillai R. K, et al. Rare cancers: Challenges & issues. Indian J Med Res. 2017;145(1):17–27.
- Kehrer-Sawatzki H, et al. Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants. Hum Genet. 2022;141(2):177–191.
Veeva ID: GL/ALL/0036